期刊
CLINICAL INFECTIOUS DISEASES
卷 74, 期 9, 页码 1586-1593出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/cid/ciab669
关键词
direct-acting antiviral; hepatitis C virus; health-related quality of life; opioid agonist treatment; people who inject drugs
资金
- National Institute on Drug Abuse [R01DA034086]
- Gilead Sciences [IN-337-1779]
The study examines the changes in health-related quality of life (HRQOL) throughout and after hepatitis C virus (HCV) treatment for people who inject drugs (PWID) achieving sustained virologic response (SVR).
Background Although efforts to treat hepatitis C virus (HCV) in people who inject drugs (PWID) yield high rates of sustained virologic response (SVR), the relationship between successful HCV treatment and health-related quality of life (HRQOL) among PWID is poorly understood. We examined HRQOL changes throughout HCV treatment and post-treatment for PWID achieving SVR. Methods Participants included 141 PWID who achieved SVR following HCV treatment onsite at 3 opioid agonist treatment (OAT) clinics in the Bronx, New York. EQ-5D-3L assesses 5 health dimensions (mobility, self-care, usual activities, pain/discomfort, and anxiety/depression), producing an index of HRQOL ranging from 0 to 1. EQ-5D-3L was measured at baseline; 4, 8, and 12 weeks during treatment; and 12 and 24 weeks post-treatment. Linear mixed effects regression models assessed changes in the mean EQ-5D-3L index over time. Results Mean EQ-5D-3L index baseline was 0.66 (standard error [SE] = 0.02). While over half the population reported no baseline problems with self-care (85.1%), usual activities (56.0%), and mobility (52.5%), at least two-thirds reported problems with pain/discomfort (78.0%) and anxiety/depression (66.0%). Twenty-four weeks post-treatment, proportions reporting pain/discomfort and anxiety/depression decreased by 25.7% and 24.0%, respectively. Mean EQ-5D-3L index significantly improved during treatment (P < .0001), and improvement was sustained following treatment completion, with mean EQ-5D-3L index of 0.77 (SE = 0.02) 12 weeks post-SVR. Conclusions HCV treatment led to sustained improvement in HRQOL for PWID on OAT who achieved SVR. Future research is necessary to determine whether improvements in HRQOL can be sustained beyond 12 weeks post-SVR. People who inject drugs (PWID) successfully treated for hepatitis C virus (HCV) during opioid agonist treatment (OAT) had sustained increases in health-related quality of life (HRQOL). We describe HRQOL improvements during and post successful HCV treatment for PWID on OAT.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据